

BICO appoints COO

BICO Group is pleased to announce the appointment of Marius Balger as Chief Operating Officer (COO), as BICO continues to accelerate its growth journey across geographies and business strategies. Mr. Balger will be part of the Executive Management team and report directly to President & CEO Erik Gatenholm.

As COO, Mr. Balger will take office 1 March 2023 and lead the strategic development of BICO's operational efficiency and cost control. Mr. Balger brings nearly 20 years of experience in the global life science industry, most recently serving as Senior Vice President, Commercial Operations at **Tecan AG**, a public life science company headquartered in Zurich, where he has worked since 2017. Before Tecan AG, Mr. Balger had a long and esteemed career as CEO, successfully growing a global Contract Development and Manufacturing Organization for life science and in-vitro diagnostics laboratory instrumentation.

"I am thrilled to welcome Marius to our team. BICO has grown rapidly and matured significantly over the past several years, both in terms of investment strategies and product portfolio scope, into a global, leading life science tools provider. With his breadth and depth of operational experience, I am confident that Marius has the skills, vision, and persistence to put the right competencies, processes, and strategies in place so that we can deliver profitable growth."

Erik Gatenholm, President & CEO BICO Group

"I am very passionate about the journey BICO Group is on and impressed with the company's rapid development, the ability and focus of changing and streamlining working methods by combining tech and biology. I am happy to join and excited to contribute alongside a great team."

Marius Balger

In line with BICO's previously communicated strategy with a focus on cost control, operational efficiency, and decentralized organizational structure the Executive Management of BICO Group will, as of today, January 5, 2023, consist of the following people: President and CEO Erik Gatenholm; CTO Hector Martinez; CFO Jacob Thordenberg and SVP & General Counsel & HR Lotta Bus. As of 1 March 2023, both COO Marius Balger and Head of Corporate Development & M&A Artur Aira are included in the Executive Management team.

For further information, please contact:

Erik Gatenholm, President & CEO, BICO Group AB

Telephone US: +1 (650) 515-5566

Telephone Sweden: +46 73 267 0000

Email: eg@bico.com

Lotta Bus, SVP & General Counsel & HR, BICO Group AB

Telephone: +46 70 611 7508

Email: lb@bico.com

PRESS RELEASE

05 January 2023 08:00:00 CET



This information is information that BICO Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-01-05 08:00 CET.

About BICO

BICO is a leading provider of life science solutions and laboratory automation that enable more efficient development of new treatments with more specificity and less need for animal testing.

The company uses bioconvergence as its operating system, combining advanced technologies with biology to streamline and automate workflows within the pharmaceutical and biopharma industries.

With 32,000+ instruments installed in over 65 countries, BICO products and solutions are found in more than 3,500 laboratories, including the world's top 20 pharmaceutical companies, and have been cited in over 11,000 publications.

Operating through three business areas – Bioprinting, Biosciences and Bioautomation – the BICO Group strives towards the long-term ambition of enabling the reduction the world's organ shortage and speeding up drug development to create the future of life-saving treatments.

BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. www.bico.com

Attachments

[BICO appoints COO](#)